Cwm, LLC Krystal Biotech, Inc. Transaction History

Cwm, LLC

$20.6 Billion
Q1 2024

A detailed history of Cwm, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Cwm, LLC holds 23,850 shares of KRYS stock, worth $4.23 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

23,850

Previous 30,569 21.98%

Holding current value

$4.23 Million

Previous $3.79 Million 11.92%

% of portfolio

0.02%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 05, 2024	SELL	$108.01 - $179.35 $725,719 - $1.21 Million	-6,719 Reduced 21.98%	23,850 $4.24 Million
Q4 2023 Feb 01, 2024	SELL	$96.0 - $128.29 $168,672 - $225,405	-1,757 Reduced 5.44%	30,569 $3.79 Million
Q3 2023 Oct 11, 2023	SELL	$108.51 - $130.22 $151,371 - $181,656	-1,395 Reduced 4.14%	32,326 $3.75 Million
Q2 2023 Aug 03, 2023	SELL	$78.48 - $130.32 $113,325 - $188,182	-1,444 Reduced 4.11%	33,721 $3.96 Million
Q1 2023 Apr 28, 2023	SELL	$72.39 - $84.27 $142,246 - $165,590	-1,965 Reduced 5.29%	35,165 $2.82 Million

Q4 2022 Feb 01, 2023	SELL	$63.14 - $79.9 $394,877 - $499,694	-6,254 Reduced 14.42%	37,130 $2.94 Million
Q3 2022 Oct 27, 2022	SELL	$64.85 - $82.4 $114,135 - $145,024	-1,760 Reduced 3.9%	43,384 $3.02 Million
Q2 2022 Jul 28, 2022	SELL	$48.93 - $73.47 $350,289 - $525,971	-7,159 Reduced 13.69%	45,144 $2.96 Million
Q1 2022 Apr 21, 2022	SELL	$51.99 - $72.11 $396,787 - $550,343	-7,632 Reduced 12.73%	52,303 $3.48 Million
Q4 2021 Jan 31, 2022	SELL	$39.81 - $88.24 $86,666 - $192,098	-2,177 Reduced 3.5%	59,935 $4.19 Million
Q1 2021 Sep 15, 2021	BUY	$59.42 - $85.46 $124,722 - $179,380	2,099 Added 3.5%	62,112 $4.22 Million
Q1 2021 Apr 27, 2021	SELL	$59.42 - $85.46 $124,722 - $179,380	-2,099 Reduced 3.38%	60,013 $4.62 Million
Q4 2020 Sep 15, 2021	BUY	$40.64 - $61.38 $182,351 - $275,412	4,487 Added 7.79%	62,112 $4.22 Million
Q4 2020 Jan 27, 2021	SELL	$40.64 - $61.38 $182,351 - $275,412	-4,487 Reduced 7.22%	57,625 $3.46 Million
Q3 2020 Sep 15, 2021	BUY	$37.76 - $48.49 $2.35 Million - $3.01 Million	62,112 New	62,112 $4.22 Million
Q3 2020 Oct 19, 2020	SELL	$37.76 - $48.49 $2.35 Million - $3.01 Million	-62,112 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$37.03 - $60.0 $2.3 Million - $3.73 Million	62,112 New	62,112 $4.22 Million
Q2 2020 Jul 22, 2020	SELL	$37.03 - $60.0 $2.3 Million - $3.73 Million	-62,112 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$35.02 - $65.64 $2.18 Million - $4.08 Million	62,112 New	62,112 $4.22 Million
Q1 2020 Apr 28, 2020	SELL	$35.02 - $65.64 $2.18 Million - $4.08 Million	-62,112 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$33.17 - $65.23 $2.06 Million - $4.05 Million	62,112 New	62,112 $4.22 Million
Q4 2019 Jan 27, 2020	SELL	$33.17 - $65.23 $2.06 Million - $4.05 Million	-62,112 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$34.72 - $51.3 $2.16 Million - $3.19 Million	62,112 New	62,112 $4.22 Million
Q3 2019 Oct 22, 2019	SELL	$34.72 - $51.3 $2.16 Million - $3.19 Million	-62,112 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$27.2 - $41.2 $1.69 Million - $2.56 Million	62,112 New	62,112 $4.22 Million
Q2 2019 Jul 31, 2019	SELL	$27.2 - $41.2 $1.69 Million - $2.56 Million	-62,112 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$19.86 - $32.9 $1.23 Million - $2.04 Million	62,112 New	62,112 $0

Others Institutions Holding KRYS

# of Institutions

262

Shares Held

21.5M

Call Options Held

462K

Put Options Held

723K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.56B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account